semaj83/ctmatch_classification huggingface dataset:
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Central Nervous System Disease Cerebrovascular Accident Stroke Patients must be aged 18 or above with subacute (at least 3 months post stroke) thromboembolic or hemorrhagic strokes with impaired motor function in at least one of the limbs but capable of performing the required motor tasks. Assessment of the initial functional state will be taken at the initial visit at the NINDS Stroke Neurorehabilitation Clinic. Patients with additional stroke(s) during the length of the protocol will not be excluded from the study if the conditions stated in the are satisfied  Patients with a history of alcohol or drug abuse, poor motivational capacity, or language disturbances, particularly of receptive nature or with serious cognitive deficits (defined as equivalent to a mini-mental state exam score of 23 or less) Patients with medical or technical contraindications to MRI procedures (e.g. metal braces, pacemakers, cochlear devices, surgical clips, and other metal/magnetic implants); claustrophobia; and pregnancy Patients who are unable to comply with the motor testing protocol
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Parkinson's Disease Idiopathic Parkinson's in accordance to UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Born and raised in Denmark  >50 years  Cerebrovascular disease Dementia not caused by Parkinson's Disease Metabolism anomaly Abuse of drugs, medication or alcohol History of head injuries Severe psychiatric disorder, excluding depression Resident outside the region of Aarhus h) DBS -
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 1.0-18.0,  Leukemia, Lymphocytic, Acute ALL, healthy
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 65.0-90.0,  Healthy Enrolled in WHIMS At least 65 years old Not diagnosed with dementia  Women younger than 65 years of age Have dementia not enrolled in WHIMS
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Amyotrophic Lateral Sclerosis Neurodegenerative Disease Motor Neuron Disease In-patients with probable or definite ALS, ages 18 staying on the neurology floor of Hahnemann Hospital  In-patients who do not meet the of the diagnosis of ALS
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Amyotrophic Lateral Sclerosis Neurodegenerative Disease Motor Neuron Disease Medical Subjects Be able to give consent themselves or via a legally authorized representative Diagnosed with a neuromuscular disease and have limited ability to communicate Be able to see visual cues such as targets or letters presented on the screen, and/or ability to hear auditory cues such as tones or words presented through speakers or earphones Be able to understand and remember instructions concerning participation Healthy control subjects Be able to consent to give consent themselves or via a legally authorized representative Be able to see visual cues such as targets or letters presented on the screen, and/or ability to hear auditory cues such as tones or words presented through speakers or earphones Be able to understand and remember instructions concerning participation  Individuals with cognitive impairments that would impact their ability to follow the instructions
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 55.0-55.0,  Spinal Cord Injury at C5-C7 Level With Incomplete Lesion an incomplete C6 ASIA C (Central Cord) spinal cord injury lower motor function impaired and suffers from significant spasticity (Ashworth scale 4) able to ambulate approximately 10-20 feet with a rolling walker and minimal assistance has sufficient endurance to complete at least two 20-minute therapy sessions per day cognitive abilities are intact  psychiatric diagnosis medical contraindications history of bleeding disorders allergy to anesthesia acute or progressive disease active implantable device
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-79.0,  ALS (Amyotrophic Lateral Sclerosis) and  Subject will be a veteran with El Escorial "Lab Supported Probable" or more definite diagnosis of ALS Subject will have lost the ability to communicate either verbally or in writing (item 1 or item 4 on the ALS Functional Rating Scale-Revised (ALSFRS-R) score of 0, Appendix A)  Subject will be an adult (age >18) Subject will be living at home Subject will be living within 100 miles of the participating study site Subject will have corrected visual acuity of at least 20/80 Subject will have the ability to read and understand 6th grade English text on a computer screen Subject will be able to indicate willingness and understanding of the consent form (using their existing method of communication) Subject will be able to identify one significant other Subject will identify one system operator (person that agrees to be trained and set up the BCI). This person can be the significant other
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Multiple Sclerosis established SPMS according to the McDonald  Patients with a history of drug/alcohol abuse, a premorbid (pre MS) psychiatric history, a head injury with loss of consciousness and a concurrent physical disease requiring medical attention (eg. cardiovascular disease etc), MRI contraindication including implants, pacemaker, aneurysm clips and known renal impairment
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 40.0-75.0,  Atrophic Vaginitis Postmenopausal women (no menses for the previous 12 months) Dryness, itching or burning in and around the vagina Discontinued hormone replacement therapy (either local or systemic) at least 3 months  Known, suspected, or history of cancer of the breast Known, or suspected estrogen dependent neoplasia (ovarian, endometrial) Known hypersensitivity to any component of the medications or base creams Active deep vein thrombosis, pulmonary embolism, or history of these conditions Active or recent (within the past year) arterial thromboembolic disease (stroke, myocardial infarct) Liver dysfunction or disease with elevation of aspartate aminotransferase (AST)>1.5x upper level of normal (ULN); Normal for females is 8-43 U/L Undiagnosed abnormal genital bleeding Known chronic lichen sclerosis Known, untreated vaginal infection Not had a normal screening mammogram within the last 15 months
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Atrophic Rhinitis Symptoms of atrophic rhinitis, with previous clinical treatment without good results  Patients with mental illness
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Estrogen Receptor Her-2 Pgr Diagnosis of breast cancer Node positive OR high-risk node negative disease Tumor > 1.0 cm in diameter No locally advanced, inflammatory, or metastatic breast cancer Previously treated with 4 courses of anthracycline-containing chemotherapy (i.e., doxorubicin and docetaxel OR doxorubicin and cyclophosphamide) Enrolled on clinical trial ECOG-E2197 Adequate tumor material available in ECOG Pathology Coordination Center Previously consented to future cancer-related research Hormone receptor status known Female
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 30.0-60.0,  General Paresis EEG MR  Serological test
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Traumatic Brain Injury Control subjects from 18-50 Patients from 18-50 who have suffered TBI  Substance abuse Irremedial sensory deficits (blindness, deafness) Primary psychiatric disorder Neurological disease unrelated to TBI
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Human Immunodeficiency Virus Hepatitis B Hepatitis C Human T-lymphotropic Virus I & II Creutzfeldt-Jakob Syndrome HIV Infections deferred blood donor status, and deferral due to a positive result of a routine blood test for HIV, or hepatitis B, or hepatitis C, or HTLV, or having been identified as at risk of vCJD; and deferral occured in 2008 or 2009 (2007 for the pilot; 2005 for those at risk of vCJD and the control group); and donor registered at one of the NHSBT centres (English Blood Service in England and Wales)  not a blood donor; or no record of notification having taken place; or a member of Armed Forces or other profession where contact at the address provided could lead to a breach of confidentiality; or deferred before 2008 (if not in the pilot or notified of increased risk of vCJD) deferred as a result of a non-routine test or syphilis infection only; or donor registered with and notified by the Welsh, Scottish or Northern Irish Blood Services
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vaginitis Dyspareunia Breast Neoplasms Histologically or cytologically confirmed breast cancer (any stage) Currently be using an aromatase inhibitor (anastrazole, exemestane or letrozole) for primary or adjuvant breast cancer treatment Must have complaints of vaginal itching, vaginal dryness and/or dyspareunia Not undergoing active chemotherapeutic or radiotherapeutic treatment Age >18 years Life expectancy of greater than 2 months CALGB (ZUBROD) performance status <3 Post-menopausal defined by absence of menses for at least 12 months and/or an FSH >25. Not post-menopausal as a function of medications intended to suppress ovarian function, such as gonadotropin releasing hormone agonists. Surgically post-menopausal subject eligible The effects of topical testosterone cream on the developing human fetus at the recommended therapeutic dose are unknown. For this study only post-menopausal women are included and all women of child-bearing potential are excluded. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately  Patients who have not recovered from adverse events due to chemotherapeutic agents administered more than 4 weeks earlier History of allergic reactions attributed to compounds of similar chemical or biologic composition to testosterone or the emollient delivery cream used in the study Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements Pregnant women and women who are breast-feeding are excluded from this study because it is limited to post-menopausal women
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Shock, Septic patient (or representative) received the information notice patient has hemodynamic insufficiency of non-traumatic or cardiogenic origin associated with severe sepsis (treated with Noradrenalin) and organ dysfunction, hypoperfusion or hypotension body temperature > 38.3°C or < 36°C heart rate > 90 bpm Tachypnea > 20 C/min or PaCO2 < 32 mmHg or mechanical ventilation leukocytes > 12000 µL-1 ou < 4000 µL-1 ou > 10% immature forms oliguria < 0.5 ml/kg/h for at least 2 hours abrupt alteration (24 h) of conscienceness thrombocytopenia < 100 000 G/L or disseminated intravascular coagulation mottled skin and / or capillary refill time> 3 sec  patient is dying or limitation or cessation of active treatment patient is already included in another trial patient or family refusal patient not affiliated with a social security system
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 50.0-80.0,  Parkinson's Disease Medical clearance to perform an exercise tolerance test and training program A diagnosis of PD at stage 2 on the Hoehn and Yahr scale  A neurological condition other than PD/ Anyone who is currently taking any vitamin supplementation Smokers Anyone currently engaged in weight training
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Alzheimer's Disease Gait Apraxia Impaired Cognition All elderly patients from the University Memory Center of Angers University Hospital Able to walk without any walking aid on 15 meters Mini-Mental Status Examination score > 10 Being affiliated to a social security regime  Mini-Mental Status Examination score ≤ 10 Subject suffering from pre-existing impellent disturbances History of cerebrovascular accident or other cerebro-spinal pathology Poor workmanship of the written or oral French language Use of walking aid such as walking frame with wheels or tricycle Acute medical or surgical disease in the past 3 months Refusal to participate (or trustworthy person) Near visual acuity < 2/10
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 30.0-80.0,  Stroke for patients wth stroke Age 40-80 years sustained a single stroke between 3-24 months prio t study leading to upper limb paresis have at least Stage 3/7 arm control (mild to moderate motor deficits) on the Chedoke-McMaster Scale <81 yrs old to minimize confounding effects of age-related changes in sensorimotor functions  for patients wth stroke other neurological or orthopaedic problems that may interfere with interpretation of results significant deficits in attention, constructional skills, neglect and apraxia shoulder subluxation, arm pain lack of endurance as judged by a physician undergoing other therapy, surgery or medical procedures within the study period for healthy control subjects Age 40-80 years for control subjects any neurological or orthopaedic problems that may interfere with interpretation of results
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Mumps Subjects with upper or lower limb spasticity Subjects must use botulinum injection for the first time